Adenosine Therapeutics (ATL), located in Charlottesville,
VA, is a drug discovery and development company that
was co-founded in 1999 by University of Virginia (UVa)
Professor Joel Linden and entrepreneur Robert Capon
(one of three cofounders of Virologic, NASDAQ: VLGC.)
Through an in-license agreement with the University
of Virginia Patent Foundation, ATL was granted exclusive,
worldwide rights to the University's adenosine-related
patent portfolio, including apadenoson, developed as Stedivaze, a cardiac stress agent
for use in diagnosis of coronary artery disease. Stedivaze was shepherded by
ATL to the end of Phase II development before ATL sold substantially
all its assets to Clinical Data, Inc. (CLDA) in 2008. CLDA and its
successors carried on development into late Phase III.
At the end of 2012, ATL reacquired many of its programs, including Stedivaze.
Stedivaze is now more than half way through Phase III trials.